What Has Been the Growth of the Biomarker Discovery Outsourcing Services Market So Far?
The biomarker discovery outsourcing services market has seen considerable growth due to a variety of factors.
• The biomarker discovery outsourcing services market has expanded rapidly in recent years. It will grow from $14.58 billion in 2024 to $17.01 billion in 2025, at a CAGR of 16.7%.
The growth is driven by an increasing disease burden, demand for pharmaceutical R&D, favorable regulatory conditions, cost-effective solutions, research collaborations, and globalization.
What Are the Future Growth Projections for the Biomarker Discovery Outsourcing Services Market?
The biomarker discovery outsourcing services market is expected to maintain its strong growth trajectory in upcoming years.
• The biomarker discovery outsourcing services market is expected to grow to $31.22 billion by 2029, at a CAGR of 16.4%.
Growth is driven by the expansion of personalized medicine, AI and machine learning integration, precision oncology growth, biomarker validation services, regulatory support, and targeted therapy demand. Trends include precision medicine adoption, technological advancements, companion diagnostics demand, expanded drug development pipelines, AI/ML integration, global market expansion, and a focus on cost-effectiveness.
What Are The Core Factors Supporting Growth In The Biomarker Discovery Outsourcing Services Market?
The growing emphasis on personalized medicine is expected to stimulate the growth of the biomarker discovery outsourcing services market. Personalized medicine, which tailors treatment based on an individual's genetics and lifestyle, is gaining momentum due to its ability to improve patient outcomes. Outsourcing biomarker discovery aids in delivering customized diagnostic and therapeutic solutions. In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to six in 2022. As personalized medicine continues to expand, it is driving the growth of the biomarker discovery outsourcing market.
What Are The Major Segments Within The Global Biomarker Discovery Outsourcing Services Market?
The biomarker discovery outsourcing services market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints
2) By Discovery Phase: Biomarker Identification, Biomarker Validation, Biomarker Profiling, Biomarker Panel Development, Biomarker Selection
3) By Therapeutic Area: Oncology, Cardiology, Neurology, Autoimmune Diseases, Other Therapeutic Areas
4) By End Use: Pharmaceutical Companies, Biotechnology Companies
Subsegments:
1) By Predictive Biomarkers: Disease Risk Assessment, Therapy Response Prediction, Personalized Medicine Guidance
2) By Prognostic Biomarkers: Disease Progression Prediction, Patient Survival Forecast, Recurrence Risk Assessment
3) By Safety Biomarkers: Toxicity Prediction, Drug Safety Evaluation, Adverse Effect Risk Assessment
4) By Surrogate Endpoints: Clinical Trial Outcome Indicators, Disease Progression Monitoring, Therapy Efficacy Tracking
Pre-Book The Biomarker Discovery Outsourcing Services Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Biomarker Discovery Outsourcing Services Market?
Major players in the biomarker discovery outsourcing services market are focusing on improving patient outcomes through multiplexed biomarker assays, including the immunoproteomic discovery platform. In October 2023, Sengenics Corporation LLC, a Singapore-based precision medicine firm, launched the i-Ome Discovery platform, which combines immunology and proteomics to identify autoantibodies associated with disease. This platform aids academic and clinical biopharmaceutical research teams by advancing immune biomarker discovery and providing insights into the relationship between proteins, the immune system, and diseases.
Who Are the Key Players In The Biomarker Discovery Outsourcing Services Market?
Major companies operating in the biomarker discovery outsourcing services market are:
• Thermo Fisher Scientific Inc.
• Labcorp Drug Development Inc.
• ICON plc
• Eurofins Scientific SE
• WuXi AppTec Co. Ltd.
• Syneos Health Inc.
• Intertek Group plc
• Charles River Laboratories International Inc.
• Parexel International Corporation
• QIAGEN N.V.
• Medpace Inc.
• Bioclinica Inc.
• Evotec SE
• GenScript Biotech Corporation
• Precision for Medicine Inc.
• BioAgilytix Labs LLC
• Celerion Inc.
• Frontage Laboratories Inc.
• SomaLogic Inc.
• Selvita S.A.
• BioIVT LLC
• Discovery Life Sciences LLC
• Metabolon Inc.
• Caprion Proteomics Inc.
• Canopy Biosciences LLC
• Crown Bioscience Inc.
What Is The Most Dominant Region In The Biomarker Discovery Outsourcing Services Market?
North America was the largest region in the biomarker discovery outsourcing services market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker discovery outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
